2023-07-16-世界卫生组织-Immunization_Liberia_2023_country_profile_28页_429kb

Summary of Liberia Immunization Coverage (WHO and UNICEF 2022 Revision)

Overview

• Time Period Covered: Data spans from 2011 to 2022.
• Sources: Estimates based on national administrative data, surveys, and interpolated data. Each estimate has a grade of confidence (GoC) reflecting data reliability.
• Key Challenges: Frequent vaccine stockouts, financial constraints, operational issues, and service disruptions during the Ebola (2014-2015) and COVID-19 (2020-2021) outbreaks.

Immunization Coverage Details:

| Vaccine/Disease | Range (2011-2022) | 2022 Coverage | GoC | Main Challenges |

BCG (Tuberculosis) | 54-93% | 67% | D-R- | Vaccine stockouts in 2022, 2021, 2020; no direct supporting data. |
DTP1 (Diphtheria/Tetanus/Pertussis)| 66-98% | 81% | S | Concerns with caregiver recall in 2014; calibration to 2018 levels in some years. |
DTP3 | 54-95% | 78% | R+ | Generally stable trend; disruptions noted in 2018/2019 due to Ebola and financial/logistical issues. Surveys modified for recall bias. |
MCV1 (Measles) | 44-94% | 74% | D+ | Variable data quality; calibration based on earlier trends in some years; measles outbreaks in 2018 likely due to coverage gaps. |
IPV1 (Inactivated Polio)| Not available 2011-2016 | 29-65%| D-R | IPV1 introduced in 2017; calibration trends used; limited initial data support. |

Additional key vaccines (not all included in summaries above):

• MCV2 remains around 35-59% coverage globally for 2022.
• Rotavirus (RotaC) shows low coverage from 48% in 2016 to 67% stabilize in 2022.
• Haemophilus influenzae type b (Hib3) coverage is 56-92%, has variability based on surveys.
• Pneumococcal conjugate vaccine (PCV3) coverage ranges from 38% to 92%.
• Polio (Pol3/POL V) – varies from 52-74% in 2022; calibrated frequently.
• Hepatitis B (HepB3) shows higher coverage (68% to 92%).
• Yellow Fever (YFV) coverage around 65% in 2022.

Grade of Confidence

• R+: High support from reported data, recalculated denominator, and recent surveys.
• D-R: Often based on administrative data with calibration trends, sometimes limited or absent surveys; data may not fully reflect reality.
• S: Supported by surveys, but possible biases.

Periodic Disruptions

• 2014-2015: Ebola outbreak severely disrupted services, leading to lower coverage estimates.
• 2020: Shortages exacerbated by COVID-19, noted in multiple vaccines.
• 2019: General declines due to combined financial and logistical issues.

Recommendations

• Enhanced surveillance using multiple data sources to improve quality.
• Strengthened strategies to manage vaccine availability and track administrative vs. survey-based data.

Disclaimer: Coverage estimates should be used cautiously, as data quality varies. Challenges noted may impact the accuracy and reliability of each estimate.